🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. NKTR-102 145 mg/m2

    Nektar Therapeutics UK Limited

    Malignant Solid Tumor

    phase 2 small molecule completed

    1 trial

  2. NPSP795

    Takeda

    Autosomal Dominant Hypocalcemia (ADH)

    phase 2 small molecule completed

    1 trial

  3. NanoDOX Hydrogel

    United Therapeutics Europe Ltd

    Orthopedic Trauma Wounds

    phase 2 small molecule terminated

    1 trial

  4. Nemtabrutinib, Zilovertamab vedotin, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  6. OT-101

    Oncotelic Therapeutics

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  7. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  8. Open-label, safety, tolerability and proof of concept study to evaluate the use of ANXV (recombinant human Annexin A5 protein) in the treatment of patients with either Diabetic Retinopathy or recent onset Retinal Vein Occlusion

    Lacuna Pharma Pty Ltd

    Diabetic Retinopathy, Retinal Vein Occlusion

    phase 2 other active

    1 trial

  9. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, GEMCITABINE, IPILIMUMAB, SOTORASIB, ODM-212 5 mg coated tablet, ODM-212 40 mg coated tablet

    Orion Laboratories Pty.

    Neoplasms benign malignant and unspecified (incl. cysts and polyps)

    phase 2 small molecule active

    1 trial

  10. PEMBROLIZUMAB, PM54

    Lacuna Pharma Pty Ltd

    Advanced malignancies

    phase 2 small molecule active

    1 trial

  11. PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, GEN1055 DP, CISPLATIN, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  12. Panzem Nanocrystal Colloidal Dispersion

    CASI Pharmaceuticals

    Recurrent Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  13. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  14. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial

  15. Paxalisib

    KAZIA THERAPEUTICS LTD

    Malignant Primary Gliomas

    phase 2 small molecule active

    1 trial

  16. Pedmark® STS

    FENNEC PHARMACEUTICALS INC.

    Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  17. Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma

    The George Institute

    Malignant Peritoneal Mesothelioma

    phase 2 other active

    1 trial

  18. Pre-operative chemotherapy

    Nanjing Zenshine Pharmaceuticals

    Gastric Cancers

    phase 2 small molecule active

    1 trial

  19. Prednisone

    Nanjing Children's Hospital

    Henoch-Schoenlein Purpura Nephritis

    phase 2 small molecule active

    1 trial

  20. ProHema-CB

    Zafatek

    Hematologic Malignancies

    phase 2 mab terminated

    1 trial

  21. ProTmune

    Zafatek

    Hematologic Malignancies

    phase 2 mab completed

    1 trial

  22. QR-1123

    ProQR Therapeutics N.V.

    Autosomal Dominant Retinitis Pigmentosa

    phase 2 small molecule active

    1 trial

  23. RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB

    Takeda

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

  24. Ramelteon and doxepin

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources